Disparities of trastuzumab use in resource-limited or resource-abundant regions and its survival benefit on HER2 positive breast cancer: A real-world study from China
The Oncologist Aug 19, 2017
Li J, et al. – In this study, trastuzumab was assessed for its actual use and the effectiveness in the real world in China. The use of trastuzumab varied in different regions and different treatment stages, and it benefited both early stage breast cancer (EBC) and metastatic breast cancer (MBC) patients.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
